All kinds of pharmaceutical services.
Two newer omicron subvariants, BA.4 and BA.5, are both increasing in our community. "These variants ebb and flow across the country. Now it's our turn to be dealing with BA.4 and BA.5 as the situation evolves. We should anticipate the emergence o...
See more
Six weeks after Clovis voluntarily discontinued its third-line use of ovarian cancer drug Rubraca in the United States for safety reasons, Europe’s Committee for Medicinal Products for Human Use has concurred with the action. The CHMP recommends t...
See more
Poolbeg Pharma, a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, has received ethics and competent authority approval to commence its Lipopolysaccharide (LPS) human challenge clinical trial for PO...
See more
Makromed.az
MGC Pharmaceuticals Ltd., a European based bio-pharma company specialising in the production and development of phytomedicines, is pleased to announce the upcoming launch of a data collection app and machine learning algorithm, ZAM, developed in conj...
See more
Makromed.az
TetraScience has added capacity for manufacturing and quality control data to its cloud-based software platform. Boston-headquartered TetraScience announced the system expansion this week, citing the ability to monitor sensors and real-time device...
See more
Zydus Worldwide DMCC has received final approval from the US Food and Drug Administration (FDA) to market the product Zydus Lifesciences said its subsidiary has received approval from the US health regulator to market antifungal Efinaconazole Topi...
See more
Merck (NYSE:MRK) has announced that it will stop the Phase 3 LYNK-003 trial focused on Lynparza (olaparib) with or without bevacizumab for patients with unresectable or metastatic colorectal cancer. Two experimental arms in the trial, one focused on ...
See more
Makromed.az
The industry reported 115 Venture Capital (VC) deals worth $3.7 billion in June 2022, compared to the last 12-month average (June 2021 to May 2022) of 161 deals worth $4.3 billion. The pharma industry reported 61 deals worth $6.4 billion as compar...
See more
Astellas Pharma (TSE:4503) has revealed that the FDA has slapped a clinical hold on its Phase 1/2 FORTIS Pompe disease study after observing a serious adverse event (SAE) — peripheral sensory neuropathy — in a trial participant. Peripheral sensory...
See more
Drug sales in 2021 hit record heights, with a handful of pharmaceutical companies handsomely rewarded for creating COVID-19 vaccines and treatments. Pfizer alone raked in $36.9 billion in sales from the Comirnaty vaccine it developed jointly with ...
See more
Azərbaycanca 
Русский